TLDR
-
Immatics stock trades at $9.69 after announcing ESMO 2026 presentations
-
Company will present new data from three PRAME therapy programs
-
Anzu-cel and IMA203CD8 studies highlight cell therapy progress
-
IMA402 data expands focus on PRAME-targeted cancer treatments
-
Immatics continues developing treatments across multiple solid tumors
Immatics N.V. traded at $9.69, gaining 3.09%, after announcing three clinical presentations for ESMO Congress 2026. The company will showcase data from its PRAME-focused cancer treatment programs in Madrid, Spain. The presentations will cover cell therapies and bispecific programs across several solid tumor indications.
Immatics Expands PRAME Cancer Therapy Portfolio Ahead of ESMO 2026
Immatics will present new clinical findings from its precision oncology pipeline during the European Society for Medical Oncology Congress. The event will run from October 23 to 27, 2026. The company will release full abstracts through the ESMO platform on October 19, 2026.
The upcoming presentations will highlight three clinical-stage programs targeting PRAME-positive cancers. These programs include anzu-cel, IMA203CD8, and IMA402. The data will provide updates from multiple cancer types and treatment approaches.
PRAME represents a therapeutic target found in more than 50 cancer types. Immatics has developed a broad PRAME franchise with multiple treatment candidates. The company continues advancing both T-cell therapies and TCR-based bispecific treatments.
The company’s PRAME pipeline includes two therapeutic approaches and several combination strategies. These programs aim to address different solid tumors through immune-based mechanisms. Immatics continues expanding clinical research across various cancer settings.
Anzu-cel and IMA203CD8 Studies Highlight Cell Therapy Progress
Immatics will present Phase 1b data from anzu-cel in metastatic cutaneous and uveal melanoma. The study will focus on factors linked to longer-lasting treatment responses. The presentation will provide additional information about the durability of PRAME-directed cell therapy.
Anzu-cel uses a T-cell receptor approach designed to identify and attack cancer cells. The therapy remains one of Immatics’ leading PRAME cell therapy programs. The company continues evaluating its potential across advanced cancers.
The company will also present Phase 1 data from IMA203CD8 across multiple PRAME-positive solid tumors. The research includes durability follow-up at clinically relevant dose levels. The study covers gynecologic cancers and other tumor types.
IMA203CD8 represents another PRAME-directed T-cell therapy within Immatics’ clinical pipeline. The program aims to improve immune targeting against tumors expressing PRAME. Hence, the data may support continued development across broader cancer populations.
The oral presentation will take place during the investigational immunotherapy session at ESMO 2026. Antonia Busse, MD, will present the IMA203CD8 study. The session will include Phase 1 findings from the ongoing clinical program.
IMA402 Bispecific Program Adds Momentum to Immatics Oncology Pipeline
Immatics will also present Phase 1b data from IMA402, its PRAME-targeted TCR-based bispecific T-cell engager. The presentation will include results from patients with advanced solid tumors. The data will cover treatment at the recommended Phase 2 dose range.
IMA402 represents a different approach within Immatics’ PRAME franchise. The bispecific therapy is designed to connect immune cells with cancer cells. The program expands the company’s efforts beyond traditional cell therapy methods.
The company plans to continue developing IMA402 through expansion cohorts and combination strategies. These efforts include combinations with immune checkpoint inhibitors and other targeted treatments. Immatics is evaluating additional PRAME-focused approaches within its pipeline.
The rapid oral presentation will feature Dirk Schadendorf, MD, during the investigational immunotherapy session. The presentation will provide early clinical results from the advanced solid tumor program. The update will support the company’s ongoing research strategy.
Immatics focuses on developing treatments that improve cancer targeting precision. The company’s pipeline includes TCR T-cell therapies and TCR bispecific treatments. Its research platform supports the development of new immune-based cancer therapies.
The three ESMO 2026 presentations demonstrate the company’s continued progress in PRAME-targeted oncology research. The updates will highlight clinical developments across different tumor types. Immatics continues strengthening its position in precision cancer treatment development.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
